🇺🇸 FDA
Pipeline program

Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

D8530C00001

Phase 1 other active

Quick answer

Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer for "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer" is a Phase 1 program (other) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
Phase
Phase 1
Modality
other
Status
active

Clinical trials